CLINICAL PEARL

On December 12, 2020, ACIP recommended use of the Pfizer-BioNTech COVID-19 vaccine in persons 16 years of age and older under the FDA’s EUA.

- The Pfizer-BioNTech vaccine is an mRNA vaccine that was rigorously tested before being authorized for use in the US. mRNA technology is fairly new, but not unknown. mRNA vaccines do not contain a live virus. They are degraded quickly by normal cellular processes and do not carry a risk of causing disease in the vaccinated person. mRNA from the vaccine never enters the nucleus of the cell and does not affect or interact with a person’s DNA.

- Prior receipt of the Pfizer-BioNTech COVID-19 vaccine will not affect the results of SARS-CoV-2 nucleic acid amplification or antigen tests.

- Currently available antibody tests for SARS-CoV-2 assess IgM and/or IgG to spike or nucleocapsid proteins. The Pfizer-BioNTech COVID-19 vaccine contains mRNA that encodes the spike protein; thus, a positive test for spike protein IgM/IgG could indicate either prior infection or vaccination. To evaluate for evidence of prior infection in an individual with a history of Pfizer-BioNTech COVID-19 vaccination, a test specifically evaluating IgM/IgG to the nucleocapsid protein should be used.

- Two intramuscular doses, ideally given 21 days apart are needed for protection (95% efficacy after 2nd dose). The efficacy of a single dose has not been systematically evaluated.

- The Pfizer-BioNTech COVID-19 vaccine is not interchangeable with other COVID-19 vaccine products. Persons initiating the series with the Pfizer-BioNTech COVID-19 vaccine should complete the series with the same product. However, if 2 doses of different mRNA COVID-19 products are inadvertently administered, no additional doses of either vaccine are recommended at this time.

- The Pfizer-BioNTech COVID-19 vaccine should be administered alone with a minimum interval of 14 days before or after administration of any other vaccines. Should the Pfizer-BioNTech COVID-19 vaccine be inadvertently administered within 14 days of another vaccine, doses do not need to be repeated for either vaccine.

- Vaccination should be offered regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection. Viral or serologic testing for acute or prior infection, respectively, is not recommended for the purpose of vaccine decision-making.

- For individuals with a known current SARS-CoV-2 infection, vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation. Current evidence suggests reinfection is uncommon in the 90 days after initial infection, therefore persons with documented acute infection in the preceding 90 days may defer vaccination until the end of this period, if desired.

- There is currently no data on the safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune response.

- To avoid exposing healthcare providers and other individuals during the immunization visit, vaccination of persons with a known SARS-CoV-2 exposure in the community or outpatient setting should be deferred until the quarantine period has ended. Residents of congregate settings (e.g., LTCFs, correctional facilities, homeless shelters) may be vaccinated during their quarantine period.

- The vaccine may be administered to persons with underlying medical conditions who have no contraindications to vaccination.
COVID-19 Digest Issue 34

- There is currently no data to establish the safety and efficacy of the vaccine in persons with HIV infection, other immunocompromising conditions, or individuals who take immunosuppressive medications or therapies. These individuals may still receive COVID-19 vaccine unless otherwise contraindicated.
- Pregnant women are at increased risk of severe illness (ICU admission, mechanical ventilation and death) and might be at an increased risk of adverse pregnancy outcomes, such as preterm birth. There is currently no data on the safety of COVID-19 vaccines in pregnant women. If a woman is part of a group (e.g., Health Care Provider) who is recommended to receive a COVID-19 vaccine and is pregnant, she may choose to be vaccinated. A discussion with her healthcare provider can help her make an informed decision. Pregnant women who experience fever following vaccination should be counseled to take acetaminophen as fever has been associated with adverse pregnancy outcomes. Routine testing for pregnancy prior to receipt of a COVID-19 vaccine is not recommended.
- mRNA vaccines are not considered live virus vaccines and are not thought to be a risk to the breastfeeding infant. However, there is no data on the safety of COVID-19 vaccines in lactating women or the effects of mRNA vaccines on the breastfeeding infant or milk production/excretion. If a lactating woman is part of a group (e.g., HCP) who is recommended to receive a COVID-19 vaccine, she may choose to be vaccinated.
- Protection from the vaccine is not immediate: it will take 1-2 weeks following the 2nd dose for an individual to be considered fully vaccinated.
- Signs and symptoms following COVID-19 vaccination in trial participants have included fever, fatigue, headache, chills, myalgias and arthralgias. Most were mild, occurred within the first 3 days of vaccination and resolved within 1-2 days of onset. Adverse reactions were more commonly reported after the second dose than after the first dose and were generally more frequent and severe in persons aged 18-55 years than in those older than 55 years.
- Unless individuals develop a contraindication to vaccination, they should be encouraged to complete the series even if they develop post-vaccination symptoms. Antipyretic or analgesic medications may be taken for treatment of post-vaccination symptoms. Routine prophylaxis for the purposes of preventing symptoms is not recommended at this time, due to lack of information on the impact of use on vaccine-induced antibody responses.
- Because of reports of anaphylactic reactions in persons vaccinated outside of clinical trials, the additional following guidance is proposed:
  - A severe allergic reaction to any vaccine or injectable therapy (intramuscular, intravenous, or subcutaneous) is a precaution to vaccination at this time
  - Vaccine providers should observe patients after vaccination to monitor for the occurrence of immediate adverse reactions:
    - Persons with a history of anaphylaxis: 30 mins
    - All other persons: 15 mins
- Given the currently limited information on how well the vaccine works in the general population, how much it may reduce disease, severity, or transmission, and how long protection lasts, vaccinated persons should continue to follow current guidance to protect themselves and others, including:
  - Wearing a mask
  - Staying at least 6 ft away from others
  - Avoiding crowds
  - Washing hands often
  - Following CDC travel guidance
  - Following quarantine guidance after an exposure to someone with COVID-19
  - Following any applicable workplace or school guidance
COVID-19 Digest Issue 34

PUBLIC HEALTH UPDATES

- **Dec. 16, 2020:** San Mateo County Now Under Regional Stay At Home Order as Virus Cases, Hospitalizations Rise
- **Joint Statement of the Bay Area Health Officers:** COVID-19 vaccine will be distributed following federal, state framework
- **Office of Governor Gavin Newsom News:** Western States Scientific Safety Review Workgroup Confirms the Pfizer Vaccine is Safe and Efficacious for Public Use
- **Vaccines and Related Biological Products Advisory Committee Meeting December 10th 2020:** FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine
- **FDA Authorizes First Direct-to-Consumer COVID-19 Test System**

GUIDANCE/GUIDELINES

- **CDC COVID-19 Vaccine Recommendations and Clinical Considerations:**
  - COVID-19 Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations
  - Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine
  - Interim Considerations for COVID-19 Vaccination of Healthcare Personnel and Long-Term Care Facility Residents
  - Post Vaccine Considerations for Healthcare Personnel
  - Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine
- **CDC COVID-19 Vaccination Recommendations in Long Term Care Facilities:**
  - Importance of COVID-19 Vaccination for Residents of Long-Term Care Facilities
  - Pharmacy Partnership for Long-Term Care Program for COVID-19 Vaccination FAQs
  - Post Vaccine Considerations for Residents
- **The American College of Obstetricians and Gynecologists (ACOG)** Vaccinating Pregnant and Lactating Patients Against COVID-19
- **NIH:** The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Baricitinib for the Treatment of COVID-19
- **CDPH:** Outdoor and Indoor Youth and Recreational Adult Sports guidance
- **American Academy of Pediatrics:** Supporting Healthy Nutrition and Physical Activity During the COVID-19 Pandemic

RESOURCES

- **CDC Clinical Partner Call:** What Clinicians Need to Know About the Pfizer-BioNTech COVID-19 Vaccine
- **CDC Clinician Outreach and Communication Activity (COCA) Webinar:** What Every Clinician Should Know about COVID-19 Vaccine Safety
- **CDC COVID-19 Vaccination Communication Toolkit** For Medical Centers, Clinics, and Clinicians
- **CDC COVID-19 Vaccination webpage** – Clinical Resources for Each COVID-19 Vaccine
- **Resources for COVID-19 Vaccine Providers:**
  - COVID-19 Vaccination Program Provider Requirements and Support
  - Training Module for Healthcare Providers
  - Considerations for Planning Curbside/Drive-Through Vaccination Clinics
COVID-19 Digest Issue 34

- Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations
- Storage and Handling Toolkit
- Pfizer-BioNTech COVID-19 Vaccine (storage and handling guidance)
- COVID-19 Real Time Learning Network by CDC and IDSA
- CDC/IDSA COVID-19 Clinician Call: COVID-19 Vaccine Update - Continued
- JAMA Network: Coronavirus Vaccine Update With Anthony Fauci
- ASCO/IDSA Webinar: The COVID-19 Vaccine & Patients with Cancer
- ACIP Presentation Slides: December 11 and 12, 2020 Meeting
- Center for Infectious Disease Research and Policy - 'Stop Swapping Air' Campaign
  - The Osterholm Update: COVID-19 - Episode 32: Stop Swapping Air

ACADEMIC/RESEARCH PAPERS

- The Lancet
  - Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  - Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
  - Rapid triage for COVID-19 using routine clinical data for patients attending hospital: development and prospective validation of an artificial intelligence screening test
  - SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England

- Cell
  - Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
  - Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

- EBioMedicine
  - Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model

- Science
  - Autoantibodies against type I IFNs in patients with life-threatening COVID-19

- Annals of Internal Medicine
  - Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial
  - Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness – A Population-Based Cohort Study

- New England Journal of Medicine
  - Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

- Nature
  - Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
  - Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
  - Genetic mechanisms of critical illness in Covid-19
COVID-19 Digest Issue 34

- **Open Forum Infectious Diseases**
  - Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Healthcare Workers in Chicago

- **Clinical Infectious Diseases**
  - Risk Factors and Outcomes of Hospitalized Patients With Severe Coronavirus Disease 2019 (COVID-19) and Secondary Bloodstream Infections: A Multicenter Case-Control Study
  - Secondary attack rate and family clustering of SARS-CoV-2 infection in children of healthcare workers with confirmed COVID-19
  - A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters

- **Pediatrics**
  - COVID-19 Transmission in US Child Care Programs

- **Emerging Infectious Diseases**
  - Absence of SARS-CoV-2 Transmission from Children in Isolation to Guardians, South Korea
  - SARS-CoV-2 Infections among Recent Organ Recipients, March–May 2020, United States
  - COVID-19 and Fatal Sepsis Caused by Hypervirulent Klebsiella pneumoniae, Japan, 2020
  - Postmortem Stability of SARS-CoV-2 in Nasopharyngeal Mucosa
  - Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019

- **The Journal of Molecular Diagnostics**
  - Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples

- **JAMA**
  - Evaluation of Rooming-in Practice for Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italy
  - Infants Born to Mothers With COVID-19—Making Room for Rooming-in
  - Assessment of German Public Attitudes Toward Health Communications With Varying Degrees of Scientific Uncertainty Regarding COVID-19
  - A Nursing Researcher’s Experience in a COVID-19 Vaccine Trial
  - Behaviorally Informed Strategies for a National COVID-19 Vaccine Promotion Program
  - The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials
  - Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines
  - Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
  - An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19
  - The Need for More and Better Testing for COVID-19
  - Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System
  - Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic
  - Filtration Efficiency of Face Masks Used by the Public During the COVID-19 Pandemic

- **Materials**
  - Face Masks and Respirators in the Fight Against the COVID-19 Pandemic: A Review of Current Materials, Advances and Future Perspectives

- **The Journal of Infectious Diseases**
  - Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review
COVID-19 Digest Issue 34

**BMJ Journal**
- Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Longitudinal increases in childhood depression symptoms during the COVID-19 lockdown

**American Journal of Clinical Pathology**
- Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality

**Circulation**
- Myocardial Injury in Severe COVID-19 Compared to Non-COVID Acute Respiratory Distress Syndrome

**Neurology Clinical Practice**
- Neurologic findings among inpatients with COVID-19 at a safety-net US hospital

**American Journal of Public Health**
- Community Trace: Rapid Establishment of a Volunteer Contact Tracing Program for COVID-19

**Journal of Korean Medical Science**
- Application of Testing-Tracing-Treatment Strategy in Response to the COVID-19 Outbreak in Seoul, Korea
- Evidence of Long-Distance Droplet Transmission of SARS-CoV-2 by Direct Air Flow in a Restaurant in Korea

**MMWR**
- Trends in U.S. Emergency Department Visits Related to Suspected or Confirmed Child Abuse and Neglect Among Children and Adolescents Aged <18 Years Before and During the COVID-19 Pandemic — United States, January 2019–September 2020
- Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged <18 Years — Mississippi, September–November 2020
- Racial and Ethnic Differences in Parental Attitudes and Concerns About School Reopening During the COVID-19 Pandemic — United States, July 2020
- COVID-19 Mortality Among American Indian and Alaska Native Persons — 14 States, January–June 2020
- Estimated Resource Costs for Implementation of CDC’s Recommended COVID-19 Mitigation Strategies in Pre-Kindergarten through Grade 12 Public Schools — United States, 2020–21 School Year

**HOT OFF THE (LAY) PRESS**
- The New York Times
  - 1st Vaccination in U.S. Is Given in New York, Hard Hit in Outbreak’s First Days
  - The first coronavirus vaccine was given in the U.S., opening a new, hopeful chapter in the battle against a pandemic that has ravaged the country.
  - First Coronavirus Vaccines Head to States, Starting Historic Effort
  - U.S. hospitals are discovering that some vials of Pfizer’s coronavirus vaccine contain extra doses, and the F.D.A. said it was acceptable to use them.
  - California Today: Vaccines Come With a Dose of Caution in California
  - Hospitals Prepare for First Shots as Virus Vaccine Shipments Blanket U.S.
  - Vaccine distribution is about to begin in the virus-ravaged U.S.
  - The U.S. and Pfizer are negotiating a deal for more vaccine doses next year
COVID-19 Digest Issue 34

- FDA Advisory Panel Gives Green Light to Pfizer Vaccine
- Pfizer’s Vaccine Offers Strong Protection After First Dose
- The F.D.A. authorized Pfizer’s coronavirus vaccine for emergency use, allowing millions of highly vulnerable people to begin receiving it within days.
- How pharmacies plan to get Pfizer’s vaccine to nursing homes
- U.S. vaccine may be a day away from authorization. Now what?
- Trump Administration Plans a Rushed Effort to Encourage Americans to Be Vaccinated
- How the Vaccine Will Get From the Lab to You (interactive)
- Pregnant and Breastfeeding Women May Opt to Receive the Vaccine
- Moderna Vaccine Is Highly Protective and Prevents Severe Covid-19, Data Show
- Moderna Vaccine Is Highly Protective Against Covid-19, the F.D.A. Finds
- The F.D.A. is expected to approve the coronavirus vaccine by Moderna on Friday, ensuring that millions more Americans will have access to inoculation.
- Here’s Why Vaccinated People Still Need to Wear a Mask
- Officials Stress That the Pandemic ‘Is Not OverYet’ as U.S. Vaccinations Begin
- More than 300,000 people with the coronavirus in the U.S. have died, a wrenching toll that comes on the heels of the nation’s first vaccine shots.
- U.S. sets record for daily deaths as hospitals nationwide near or exceed capacity.
- A week after the U.S. broke a daily record for coronavirus deaths set in April, it did so again. At least 3,000 deaths were reported Wednesday.
- The Morning: Comparing virus surges
- Masks, Distancing — and Tests
- ‘There’s No Place for Them to Go’: I.C.U. Beds Near Capacity Across U.S.
- 2020 was Especially Deadly. Covid Wasn’t the Only Culprit
- Where Are Your Papers? A New Yorker Goes Home to Locked-Down France
- In Sweden, Infections and Calls for a Lockdown Are Rising
- For a Nation on Edge, Antacids Become Hard to Find

- The New Yorker
  - What We Know About Pfizer’s COVID-19 Vaccine
  - America Is Running Out of Nurses

- Nature News
  - Why emergency COVID-vaccine approvals pose a dilemma for scientists
  - Oxford COVID-vaccine paper highlights lingering unknowns about results

- Science News
  - ‘So many unknowns’: Local doctors—and pharmacies—will still decide who gets COVID-19 vaccines

- AP News
  - Many remain doubtful about getting COVID-19 vaccine
  - The Latest: Alaska reports 2nd adverse reaction to vaccine
  - Pandemic backlash jeopardizes public health powers, leaders
  - A pandemic atlas: How COVID-19 took over the world in 2020
  - Merkel backs tougher virus curbs as German deaths hit record
COVID-19 Digest Issue 34

- **STAT News**
  - FDA scientists endorse ‘highly effective’ Pfizer/BioNTech Covid-19 vaccine ahead of key panel
  - On the ground, the pledge to vaccinate 20 million against Covid-19 in December seems unrealistic
  - ‘There absolutely will be a black market’: How the rich and privileged can skip the line for Covid-19 vaccines
  - Data show panic and disorganization dominate the study of Covid-19 drugs
- **Medscape**
  - COVID-19 Vaccines: Preparing for Patient Questions
- **Washington Post**
  - Pfizer tells U.S. officials it cannot supply substantial additional vaccine until late June or July
- **CNN**
  - Supply issues hampering Pfizer providing additional vaccine faster
- **Reuters**
  - UK issues anaphylaxis warning on Pfizer vaccine after adverse reactions
  - New coronavirus strain spreading in UK has key mutations, scientists say
  - UAE says Sinopharm vaccine has 86% efficacy against COVID-19
  - Australia halts local COVID-19 vaccine development due to false HIV positives
- **National Academy for State Health Policy**
  - States Plan for Vaccinating their Populations against COVID-19
- **NPR/KQED**
  - DOD Unveils Its Coronavirus Vaccine Distribution Plan
  - For California Latinos, COVID Testing Resources Remain Scarce
  - FDA Authorizes 1st Home Coronavirus Test That Doesn't Require A Prescription
  - California Demands Amazon Comply With Subpoenas Over COVID-19 Worker Safety
  - Santa Clara County Virus Outbreak Linked to Illegal Youth Basketball Tournament
- **Bloomberg**
  - First U.S. Shipments of Pfizer Vaccine Will Be 2.9 Million Doses
  - Vaccine Rollout Hits First U.S. Snags With Delays, Allergic Case
  - First Covid Vaccines’ Triumph Raises Hope for Cancer Fight
- **Today.com**
  - What is a ‘COVID-19 passport’? Concept raises both hope and concern
- **LabCorp Press Releases**
  - LabCorp Receives FDA Authorization to Make At-home COVID-19 Collection Kits Available Through Retail
- **Roche Press Releases**
  - Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
- **The Atlantic**
  - The Pandemic’s Final Surge Will Be Brutal
- **The Economist**
  - Almost one in five Americans may have been infected with covid-19
- **The Wall Street Journal**
  - The Pro Cyclist Who Caught Covid Twice
COVID-19 Digest Issue 34

- **Ipsos**
  - As pandemic rages, minority of Americans driving most risky behavior

- **NBC News**
  - Birx says health officials are still fighting 'myths' about pandemic's spread

- **CNBC**
  - Mayo Clinic doctor studying Covid ‘long haulers’ says it might take them a year or more to recover

- **Vox**
  - The many strange long-term symptoms of Covid-19, explained
  - Anxiety and depression are following a remarkably similar curve to Covid-19 cases
  - A wild mink in Utah has Covid-19. Veterinarians fear this is just the beginning.

- **Cleveland.com News**
  - Coronavirus found in Cleveland-area sewage suggests a surge in cases is coming, official says

- **The Hill**
  - Coronavirus identified in Italy months before first confirmed case
  - CDC studies impact of 'forever chemical' exposure on COVID-19 antibodies

- **Center for Infectious Disease Research and Policy News**
  - Global cases stabilizing, but COVID deaths continue to climb
  - Kids likely not driving household COVID-19 outbreaks

- **National Geographic**
  - Exclusive: Kids catch and spread coronavirus half as much as adults, Iceland study confirms

- **Medpage Today**
  - IBD and COVID-19: Who Is at Risk?

- **Healio Cardiology**
  - Low LDL, high triglycerides may indicate mortality risk in COVID-19 hospitalization

- **The Mercury News**
  - The first 327,000 doses of the Pfizer COVID-19 vaccine arrived in California Sunday night
  - Fleeing restrictions in the rest of the region, Bay Area residents swarm to San Mateo County

- **The Los Angeles Times**
  - California again Shatters Single Day Coronavirus Case Record, more than 42,000 cases
  - California shatters single-day COVID-19 death record, with 295
  - California health officials scramble to staff medical facilities amid COVID-19 surge
  - National commission says prison inmates, guards should be among first to get COVID-19 vaccine
  - With ICUs hitting capacity, hospitals turn to desperate measures
  - Facing ‘a grim set of weeks’, California opens COVID field hospitals across the state
  - San Mateo County pleads with outsiders to stop visiting
  - Covid-19 Reaching Catastrophic Levels in LA County
  - ‘I’ve seen people die.’ COVID-19 slams Central Valley hospitals, as many resist lockdowns

- **The Press Democrat**
  - Workplaces a major driver of COVID-19 in Sonoma County

- **CBS Local News**
  - Santa Clara County’s Door-to-Door Coronavirus Testing Program Shows Promise
  - Bay Area COVID Roundup: Marin Runs Out Of ICU Rooms; State Orders 5,000 Body Bags; Livermore Parents Want Kids Back In Classrooms
COVID-19 Digest Issue 34

- San Francisco Chronicle
  - California coronavirus vaccine doses held back due to storage problems, regulatory delays
  - First Pfizer vaccines en route to Bay Area: What you need to know
  - Studies suggest AstraZeneca COVID-19 vaccine safe, effective
  - Bay Area falls to 12.9% ICU availability, triggering state’s stay-at-home order in San Mateo, Napa, Solano counties
  - Coronavirus live updates: California’s new cases skyrocket to more than 50,000 in a day
  - Charts show how bad the COVID surge has been in Bay Area counties since Thanksgiving
  - The Bay Area nears critical shortage of ICU beds, Santa Clara County at 8%
  - Life and death inside a Bay Area ICU grueling, ‘but we’ve got this’
  - ‘Our luck is beginning to wear out’: Bay Area’s brutal surge strains hospitals even as vaccine arrival imminent
  - The Bay Area is more skeptical of COVID-19 lockdowns this time. Why?
  - The risk of getting coronavirus at Bay Area schools is low. So why is fear of returning still so high?
  - Lake Tahoe shutting down to tourists Friday
  - Bay Area diners are still eating outside restaurants, whether businesses want it or not

Epidemiology Updates

- US Leads the World in Confirmed COVID-19 Cases per Johns Hopkins University Center for Systems Science and Engineering Dashboard Website
- Johns Hopkins COVID-19 in the USA – daily summary of key data on COVID-19 in the U.S.
- California COVID-19 by the numbers are available on the CDPH Website and the NYT Map and Table (includes data by county)
  - California COVID-19 Statewide Update as of December 18, 2020
- San Mateo County COVID-19 Dashboard
- Santa Clara County COVID-19 Dashboard

Additional COVID-19 Resources

- San Mateo County COVID-19 Guidance and Resources for Clinicians and Facilities – COVID-19 Digests
- Palo Alto Online tracking the coronavirus in San Mateo and Santa Clara counties
- California COVID-19 Data and Tools
- CDPH COVID-19 Assessment and Modeling Tool
- California Department of Corrections and Rehabilitations Population COVID-19 Tracking Dashboards
- COVID-19 Nursing Home Data
- HHS Coronavirus Data Hub
- CDC Interactive Serology Dashboard for Commercial Laboratory Surveys